Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare.

Journal of medical economics·2026
Same author

Clinical Use and Application of Neutropenic Diets for Patients With Cancer: A Cross-Sectional Survey of Dietitians in Australian Hospitals.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2026
Same author

A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States.

Expert opinion on biological therapy·2026
Same author

Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population.

Future oncology (London, England)·2025
Same author

Connecting research and community: a methodological framework for investigating CMV transmission in childcare settings.

Frontiers in pediatrics·2025
Same author

Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.

ACR open rheumatology·2025

Related Experiment Video

Updated: May 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Biosimilar adoption and provider performance in Medicare value-based payment models.

Basit Chaudhry1, Andrew Yue2, Ahmed Shelbaya3,4

  • 1Tuple Health, 4800 Hampden Ln, Ste 200, Bethesda, MD 20814.

The American Journal of Managed Care
|May 26, 2026
PubMed
Summary

Biosimilar adoption in cancer care significantly reduced costs for providers in the Oncology Care Model (OCM). This strategy helps manage financial risk in value-based payment models.

More Related Videos

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Related Experiment Videos

Last Updated: May 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Area of Science:

  • Health economics
  • Oncology
  • Pharmacoeconomics

Background:

  • The Oncology Care Model (OCM) incentivizes value-based care for cancer patients.
  • Biosimilar drugs offer potential cost savings compared to reference biologic agents.
  • Understanding the financial impact of biosimilar adoption on provider risk is crucial for value-based care models.

Purpose of the Study:

  • To quantify the financial risk for oncology providers under the OCM associated with biosimilar adoption.
  • To analyze real-world data on biosimilar use and its impact on total cost of care.

Main Methods:

  • Retrospective analysis of Medicare fee-for-service beneficiaries in OCM episodes (January 2019-June 2021).
  • Included episodes with bevacizumab, rituximab, trastuzumab, epoetin alfa, filgrastim, or pegfilgrastim use.
  • Financial risk defined as observed total cost of care versus OCM benchmark; primary outcome compared observed vs. hypothetical 100% reference product use.

Main Results:

  • 8851 episodes were analyzed; biosimilar adoption yielded a mean cost reduction of $1023 per 6-month episode.
  • Biosimilar use increased significantly, reaching 65% of episodes in H1 2021.
  • Mean cost reduction per episode improved nearly tenfold from H1 2019 ($201) to H1 2021 ($2060).

Conclusions:

  • Rapid biosimilar adoption in Medicare oncology episodes generated substantial cost savings.
  • Biosimilar use is a key strategy for providers to manage financial risk within value-based payment models like the OCM.